반응식
[CH3:1][C:2]1[N:3]=[CH:4][C:5]([NH:8][C:9]2[C:18]3[C:13](=[CH:14][CH:15]=[C:16]([OH:19])[CH:17]=3)[N:12]=[CH:11][N:10]=2)=[N:6][CH:7]=1.[Cl:20][C:21]1[C:22](F)=[N:23][CH:24]=[C:25]([O:27][CH2:28][CH:29](OCC)OCC)[CH:26]=1.[CH3:37][NH:38][CH3:39].O1CCCC1>>[Cl:20][C:21]1[C:22]([O:19][C:16]2[CH:17]=[C:18]3[C:13](=[CH:14][CH:15]=2)[N:12]=[CH:11][N:10]=[C:9]3[NH:8][C:5]2[CH:4]=[N:3][C:2]([CH3:1])=[CH:7][N:6]=2)=[N:23][CH:24]=[C:25]([O:27][CH2:28][CH2:29][N:38]([CH3:39])[CH3:37])[CH:26]=1참가 물질
4
실험 절차
Using 4-[(5-methylpyrazin-2-yl)amino]quinazolin-6-ol, 3-chloro-5-(2,2-diethoxyethoxy)-2-fluoropyridine and 2 M dimethylamine/tetrahydrofuran solution, and in the same manner as in Example 32 or according to a method similar to it or according to a combination thereof with an ordinary method, the entitled compound (14 mg) was obtained as a pale yellow amorphous solid.
출처 및 근거
- ORD 기록
- ord-5b3fb5f4479042eba32fefa1955e7f91
- 출처 데이터셋
- uspto-grants-2014_09
- 특허 번호
- US08846700B2
연결된 노트
불러오는 중…